Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + bevacizumab as postoperative adjuvant therapy for high-risk hepatocellular carcinoma
ChiCTR2500101131Phase 4Not yet recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab, tuvonralimab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: One-year recurrence-free survival rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500101131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101131.